Galux to conduct joint research with LG Chem on cancer drug development

신하늬 2024. 8. 26. 17:54
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

닫기
Galux, an AI drug development startup, signed an agreement to conduct joint research for cancer drug development with LG Chem, the company said Monday.

[GETTY IMAGES]

[GETTY IMAGES]

Galux, an AI drug development startup, signed an agreement to conduct joint research for cancer drug development with LG Chem, the company said Monday.

Galux will design a lead compound for new cancer treatment with its AI technology, while LG Chem will handle the optimization of the lead compound and global nonclinical and clinical trials.

Galux, established in 2020, recently introduced GaluxDesign, an antibody design method that the company explains rivals the performance of Google’s AlphaFold. The startup so far secured 26 billion won ($19.6 million) in funding from investors including LG Corp.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?
코리아중앙데일리에서 직접 확인하세요. 해당 언론사로 이동합니다.